MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- SUN PHARMA
- SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3%
SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3%
Wed, 14 Aug
SUN PHARMA has announced its results for the quarter ended June 2019. Here is a detailed performance review of the same:
SUN PHARMA Quarterly Financials
| No. of Mths Qtr. Ending | 3 Jun-18* | 3 Mar-19* | 3 Jun-19* | QoQ Change | YoY Change | |
|---|---|---|---|---|---|---|
| Net Sales | Rs m | 72,242 | 71,639 | 83,744 | 16.9% | 15.9% |
| Other income | Rs m | 1,998 | 2,815 | 2,130 | -24.3% | 6.6% |
| Turnover | Rs m | 74,239 | 74,455 | 85,874 | 15.3% | 15.7% |
| Expenses | Rs m | 56,175 | 61,471 | 63,788 | 3.8% | 13.6% |
| Gross profit | Rs m | 16,067 | 10,168 | 19,956 | 96.3% | 24.2% |
| Depreciation | Rs m | 4,016 | 4,541 | 4,571 | 0.7% | 13.8% |
| Interest | Rs m | 1,309 | 1,500 | 1,041 | -30.6% | -20.5% |
| Profit before tax | Rs m | 12,739 | 6,942 | 16,474 | 137.3% | 29.3% |
| Tax | Rs m | 1,639 | -288 | 1,461 | -10.9% | |
| Profit after tax | Rs m | 11,101 | 7,231 | 15,014 | 107.6% | 35.3% |
| Gross profit margin | % | 22.2 | 14.2 | 23.8 | ||
| Effective tax rate | % | 12.9 | -4.1 | 8.9 | ||
| Net profit margin | % | 15.0 | 9.7 | 17.5 |
Interim results exclude extraordinary / exceptional items
Year-on-Year Performance:
- The company's operating income during the quarter grew 15.9% on a year-on-year (YoY) basis. The expenses were up by 13.6% YoY during the same period.
- The company's operating profit increased by 24.2% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 23.8% in 1QFY20 as against 22.2% in 1QFY19.
- Depreciation charges increased by 13.8% and finance costs declined by 20.5% YoY, respectively.
- Other income increased by 6.6% YoY during the quarter.
- Net profit for the quarter increased by 35.3% YoY. Net profit margins during the quarter increased from 15.0% in 1QFY19 to 17.5% in 1QFY20.
Quarter-on-Quarter Performance:
- The company's operating income during the quarter grew 16.9% on a quarter-on-quarter (QoQ) basis. The expenses were up by 3.8% QoQ during the same period.
- The company's operating profit increased by 96.3% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 23.8% in 1QFY20 as against 14.2% in 4QFY19.
- Net profit for the quarter increased by 107.6% QoQ, while net profit margins increased from 9.7% in 4QFY19 to 17.5% in 1QFY20.
To see how SUN PHARMA has performed over the last eight quarters,please visit here.
SUN PHARMA Share Price Performance
Over the last one year,SUN PHARMA share price has moved down from Rs 601.7 to Rs 416.7, registering a Loss of Rs 185.0 or around 30.7%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,484.3 (down 0.7%). Over the last one year it has moved down from 14,687.0 to 12,484.3, a gain of 2,203 points (down 15.0%).
Overall, the S&P BSE SENSEX is down 0.6% over the year.
Current Valuations
At the current price of Rs 416.7, the price to earnings (P/E) ratio of SUN PHARMA stands at 28.0 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 2.4 times.
|
| |
Related Views on News
SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Aug 6, 2019 | Updated on Aug 6, 2019Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 20, 2018 | Updated on Dec 20, 2018Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)
Nov 20, 2017The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.
More Views on NewsMost Popular
Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)
Sep 12, 2019News headlines predict gloom and doom for India these days. You should ignore them.
A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)
Sep 16, 2019The stock market today is throwing up a great opportunity to pile on quality stocks.
A Recession Proof Stock You Can Bet On(Profit Hunter)
Sep 10, 2019Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.
This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)
Sep 11, 2019How financial inclusion provides a big runway for this stock recommendation.
The 5 Best Trading Opportunities I've Spotted(Profit Hunter)
Sep 13, 2019These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.
More|
| |
SUN PHARMA SHARE PRICE
Sep 20, 2019 (Close)
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA 8-QTR ANALYSIS
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster requests your view! Post a comment on "SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!